ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
RegulatorypositiveDaybuPositive
AI Analysis
Summary
Acadia Pharmaceuticals' Daybu received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for approval in Rett Syndrome, a significant regulatory milestone in Europe.
Outcome Details
CHMP (Committee for Medicinal Products for Human Use) backs Daybu for EU approval in Rett Syndrome
Importance:8/10
Sentiment:
0.80
EU approvalCHMP positive opinionRett Syndromeregulatory milestone
Related Companies
Read the original article
Published by yahoo_finance on June 29, 2026 3:15 PM